Stablepharma has partnered with a WHO pre-qualified European vaccine manufacturer as well as world-class UK academic institutions, in order to advance our work on the thermo-stabilisation of T&D containing vaccines and mRNA vaccine technologies. Stablepharma was delighted to received an Innovate UK grant to progress our work in these areas.

Projects and strategic partnerships

Stablepharma has a strategic R&D and commercialisation partnership agreement in place with the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio) with the aim to produce the world’s first ‘fridge free’ Td-StablevaX™ vaccine.

We have established partnerships with two leading UK Universities: University of Southampton to conduct our First in Human Clinical Trials for the Td vaccine; and the University of Strathclyde to progress our mRNA stabilisation project for Covid-19 vaccines.

Working with the UK’s The National Institute for Biological Standards and Control (NIBSC) to conduct animal trials we confirmed that the StablevaX™ tetanus vaccine to induce the same level of antibody response as the positive control vaccine.

Innovate UK is currently providing grant funding to Stablepharma to progress the R&D and product development work for the StablevaX™ Td vaccine.

Our white paper

StablevaX™ - a complementary technology for COVID-19 vaccines

In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never appeared starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.

StablevaX™ - a complementary technology for COVID-19 vaccines
Our white paper

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose

A world changing invention for the stabilisation of vaccines.

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose